Dermira Inc (NASDAQ:DERM) – Investment analysts at Leerink Swann lifted their FY2018 earnings estimates for Dermira in a research report issued to clients and investors on Wednesday. Leerink Swann analyst S. Fernandez now expects that the biopharmaceutical company will post earnings per share of ($3.55) for the year, up from their prior estimate of ($3.79). Leerink Swann currently has a “Outperform” rating and a $48.00 price target on the stock. Leerink Swann also issued estimates for Dermira’s FY2019 earnings at ($4.78) EPS, FY2020 earnings at ($3.09) EPS and FY2021 earnings at ($0.86) EPS.
Dermira (NASDAQ:DERM) last issued its earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.12) by ($0.09). Dermira had a negative net margin of 992.18% and a negative return on equity of 41.22%.
Other analysts have also issued reports about the stock. Needham & Company LLC reissued a “buy” rating and set a $43.00 target price (down from $46.00) on shares of Dermira in a research note on Tuesday, November 7th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Dermira in a research note on Monday, November 6th. BidaskClub raised shares of Dermira from a “hold” rating to a “buy” rating in a research note on Wednesday, December 20th. Guggenheim reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Dermira in a research note on Thursday, December 14th. Finally, Mizuho lowered their price objective on shares of Dermira from $43.00 to $39.00 and set a “buy” rating for the company in a research note on Tuesday, December 12th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $42.17.
Shares of Dermira (NASDAQ DERM) traded up $0.73 on Friday, hitting $27.98. 452,100 shares of the stock were exchanged, compared to its average volume of 801,858. The stock has a market capitalization of $1,135.62, a price-to-earnings ratio of -4.49 and a beta of 0.80. Dermira has a 1 year low of $21.35 and a 1 year high of $38.75. The company has a debt-to-equity ratio of 1.40, a current ratio of 4.68 and a quick ratio of 4.68.
A number of institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN raised its holdings in Dermira by 4.0% in the third quarter. Wells Fargo & Company MN now owns 52,995 shares of the biopharmaceutical company’s stock worth $1,431,000 after purchasing an additional 2,025 shares in the last quarter. SG Americas Securities LLC raised its holdings in Dermira by 66.8% in the second quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 2,203 shares in the last quarter. New York State Common Retirement Fund raised its holdings in Dermira by 4.8% in the third quarter. New York State Common Retirement Fund now owns 49,993 shares of the biopharmaceutical company’s stock worth $1,350,000 after purchasing an additional 2,308 shares in the last quarter. Quantbot Technologies LP raised its holdings in Dermira by 75.4% in the third quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock worth $145,000 after purchasing an additional 2,309 shares in the last quarter. Finally, Legal & General Group Plc raised its holdings in Dermira by 40.9% in the second quarter. Legal & General Group Plc now owns 9,664 shares of the biopharmaceutical company’s stock worth $281,000 after purchasing an additional 2,803 shares in the last quarter. Institutional investors and hedge funds own 99.47% of the company’s stock.
In other Dermira news, insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $27.34, for a total value of $82,020.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Christopher M. Griffith sold 18,458 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $27.05, for a total transaction of $499,288.90. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,258 shares of company stock valued at $985,873. 13.30% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: “FY2018 EPS Estimates for Dermira Inc Increased by Leerink Swann (DERM)” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/01/19/fy2018-eps-estimates-for-dermira-inc-increased-by-leerink-swann-derm.html.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.